Statins and hemoperfusion improve 28-day survival in septic shock patients
Central European Journal of Medicine, 04/27/2012Nakamura T et al.
The present study suggests that pre–existing statin use and hemoperfusion with polymyxin B–immobilized fiber (PMX–F) may separately and independently contribute to blunt the process of septic shock.
The authors examined retrospectively whether pre–existing statin and hemoperfusion with PMX–F at the time of admission were separately and independently associated with decreased overall 28–day mortality in septic shock patients.
Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study.
All patients underwent a complete history and physical examination, determination of blood chemistries.
Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX–F and HDL–cholesterol were independently correlated to 28–day survival in septic shock patients (R2=0.464).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.